Guilherme Harada
A5006571734- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Gastric Cancer Management and Outcomes
- Liver physiology and pathology
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Enzyme function and inhibition
- PI3K/AKT/mTOR signaling in cancer
- Ferroptosis and cancer prognosis
- Synthesis and biological activity
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Chemical Reactions and Isotopes
- Cancer therapeutics and mechanisms
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- RNA modifications and cancer
- Chronic Lymphocytic Leukemia Research
Hospital Sírio-Libanês
2019-2025
Memorial Sloan Kettering Cancer Center
2021-2025
Cornell University
2022-2025
University of California, Irvine Medical Center
2024
Instituto do Câncer do Estado de São Paulo
2018-2024
Kettering University
2022-2023
Sociedade Brasileira de Oncologia Clínica
2022
Cincinnati Children's Hospital Medical Center
2022
Universidade de São Paulo
2014-2021
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2017
Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC); however, a multicenter cohort of patients cancers treated osimertinib and selpercatinib for fusion-mediated has not previously published.
Abstract Activating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic a subset of papillary renal cell carcinomas. Here, using comprehensive genomic profiling among >600,000 patients, we identify activating TKD as putative driver across diverse cancers, with frequency ∼0.5%. The most common defined or likely according to OncoKB resulted amino acid substitutions at positions H1094, L1195, F1200, D1228, Y1230, M1250, and others. Preclinical modeling these alterations...
In GI cancers, anaplastic lymphoma kinase (ALK) rearrangements are extremely less frequent than in non-small-cell lung cancer but may be important to offer personalized strategies of treatment selected patients. Data about the activity and efficacy ALK inhibitors (ALKi) cancers scarce.We assembled a clinical molecular international data set pretreated patients with metastatic or nonresectable primary tumor origin documented rearrangement treated at least one line ALKi. Measurable disease as...
<div>AbstractPurpose:<p>Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There limited data on the clinical course affected patients.</p>Experimental Design:<p>We conducted an international retrospective cohort study patients with TRK fusion–driven tumors.</p>Results:<p>A total 119 were identified. The median age at time diagnosis was 4.5 years. majority reported to have a histology consistent...
<p>Supplementary Figure S1. Diagram of population patients.</p>
<p>Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) LGG: Low-grade glioma, HGG: High-grade glioma</p>
<p>Supplementary Data S1. Definition of response, Description response criteria used by sites to evaluate tumor extend resection, resection sites.</p>
The grammar in this abstract is generally correct, but there's a minor issue with sentence structure one part. Here's slightly revised version improved and flow: ROS1 tyrosine kinase inhibitors (TKIs) are highly effective ROS1-positive non-small cell lung cancer, resistance remains challenge. We investigated the activity of various TKIs against wildtype mutant ROS1, focusing on emerging L2086F mutation. Using Ba/F3 NIH3T3 models, CRISPR/Cas9-edited isogenic patient-derived lines, vivo tumor...
Objective This paper aims to describe the clinical and regulatory aspects of new drugs indications that were approved for lung, breast, prostate, colorectal cancer, from 2016 2018, in order provide health technology assessment trends oncology. Methods Data collected US Food Drug Administration (FDA) online database medications above-mentioned types cancer. regarding study characteristics information collected. Results From 53 percent FDA approvals most incident cancers oral protein kinase...
3104 Background: First-generation TRK tyrosine kinase inhibitors (TKIs) are approved in a tumor-agnostic fashion more than 40 countries for patients with NTRK fusion-positive adult and pediatric cancers. While resistance to these agents has previously been described, the exact frequency which major mechanisms of emerges is not clearly understood. Methods: Patients an NTRK-fusion-positive tumor who received first-generation TKI were eligible. We retrospectively identified those that had...
Background myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic clonal disorders. So, prognostic variables important to separate patients with similar biology and clinical outcome. We compared the importance risk stratification in primary MDS IPSS WPSS just described revision (IPSS-R), examined if obtained by bone marrow immunophenotyping could add information any scores. Methods In this prospective study 101 cases we relation patients’ overall survival WHO types, IPSS,...
While tyrosine kinase inhibitors (TKI) have shown remarkable efficacy in anaplastic lymphoma (ALK) fusion-positive advanced non-small cell lung cancer (NSCLC), clinical outcomes vary and acquired resistance remains a significant challenge. We conducted retrospective study of patients with ALK-positive NSCLC who had clinico-genomic data independently collected from two academic institutions (n = 309). This was paired large-scale genomic cohort underwent liquid biopsies 1,118). Somatic...